The rise of new psychoactive substances and psychiatric implications: A wide‐ranging, multifaceted challenge that needs far‐reaching common legislative strategies

Synthetic cannabinoid use disorder: an update for general psychiatrists

(2019) Jasmin Grigg et al.   Australasian Psychiatry

Legislation targeting head shops selling new psychoactive substances and changes in drug‐related psychiatric admissions: A national database study

(2019) Bobby P. Smyth et al.   Early Intervention in Psychiatry

Editorial: Novel Psychoactive Drugs

(2019) Liana Fattore et al.   Frontiers in Psychiatry

Synthetic cathinones: an evolving class of new psychoactive substances

(2019) João L. Gonçalves et al.   CRITICAL REVIEWS IN TOXICOLOGY

New psychoactive substances: challenges for drug surveillance, control, and public health responses

(2019) Amy Peacock et al.   LANCET

Hair testing of GHB: an everlasting issue in forensic toxicology

(2018) Francesco Paolo Busardò et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Sexualized drug use (‘chemsex’) and high-risk sexual behaviours in HIV-positive men who have sex with men

(2018) EL Pufall et al.   HIV MEDICINE

Phencyclidine-like in vivo effects of methoxetamine in mice and rats

(2018) Michael D. Berquist et al.   NEUROPHARMACOLOGY

Pharmacological profile of mephedrone analogs and related new psychoactive substances

(2018) Dino Luethi et al.   NEUROPHARMACOLOGY

Neurotoxicity screening of new psychoactive substances (NPS): Effects on neuronal activity in rat cortical cultures using microelectrode arrays (MEA)

(2018) Anne Zwartsen et al.   NEUROTOXICOLOGY

Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?

(2018) Laura Hondebrink et al.   PHARMACOLOGY & THERAPEUTICS

Replacing GHB with GBL in recreational settings: a new trend in chemsex-

(2018) Francesco Paolo Busardo et al.   CURRENT DRUG METABOLISM

Novel psychoactive substances (NPS) use in severe mental illness (SMI) patients: Potential changes in the phenomenology of psychiatric diseases

(2017) Giuseppe Bersani et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Inpatient Gamma-Hydroxybutyrate Detoxification

(2017) Louis von Theobald et al.   Journal of Addiction Medicine

Chronic Ketamine Exposure Causes White Matter Microstructural Abnormalities in Adolescent Cynomolgus Monkeys

(2017) Qi Li et al.   Frontiers in Neuroscience

From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate

(2016) Francesco Paolo Busardò et al.   Current Neuropharmacology

Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project

(2016) Tibor M. Brunt et al.   Drug Testing and Analysis

Abnormal white matter integrity in synthetic cannabinoid users

(2016) Nabi Zorlu et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening

(2016) Pertti Heikman et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

The Neurobiological Mechanisms of Gamma-Hydroxybutyrate Dependence and Withdrawal and Their Clinical Relevance: A Review

(2016) Rama M. Kamal et al.   NEUROPSYCHOBIOLOGY

Human Pharmacology of Mephedrone in Comparison with MDMA

(2016) Esther Papaseit et al.   NEUROPSYCHOPHARMACOLOGY

Use of novel psychoactive substances by inpatients on general adult psychiatric wards

(2016) Jack L Stanley et al.   BMJ Open

Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants

(2016) Cristina Miliano et al.   Frontiers in Neuroscience

A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment

(2015) Robert J. Tait et al.   CLINICAL TOXICOLOGY

Deaths of individuals aged 16-24 years in the UK after using mephedrone

(2015) Barbara Loi et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Effect of Some Psychoactive Drugs Used as ‘Legal Highs’ on Brain Neurotransmitters

(2015) Krystyna Gołembiowska et al.   NEUROTOXICITY RESEARCH

Mephedrone, Methylone and 3,4-Methylenedioxypyrovalerone (MDPV) Induce Conditioned Place Preference in Mice

(2014) Louise Karlsson et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon?

(2014) Claudio Vidal Giné et al.   Drug Testing and Analysis

From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs

(2014) Hamilton Morris et al.   Drug Testing and Analysis

Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys

(2012) Lin Sun et al.   ADDICTION BIOLOGY

Pharmacological characterization of designer cathinonesin vitro

(2012) LD Simmler et al.   BRITISH JOURNAL OF PHARMACOLOGY

Clinical toxicology of newer recreational drugs

(2011) Simon L. Hill et al.   CLINICAL TOXICOLOGY

Synthetic cannabinoid JWH-018 and psychosis: An explorative study

(2011) Susanna Every-Palmer   DRUG AND ALCOHOL DEPENDENCE

“Spice” Girls: Synthetic Cannabinoid Intoxication

(2010) Aaron B. Schneir et al.   JOURNAL OF EMERGENCY MEDICINE

Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues

(2010) Fabrizio Schifano et al.   PSYCHOPHARMACOLOGY

The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes

(2010) Helge Müller et al.   SCHIZOPHRENIA RESEARCH

Substance Abuse Among Adolescents

(2008) Steve Sussman et al.   SUBSTANCE USE & MISUSE

Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains

(2007) Chalon R. Majewski-Tiedeken et al.   DRUG AND ALCOHOL DEPENDENCE